The Role of Hematopoietic Growth Factors in Nuclear and Radiation Accidents
Exposure to total body radiation results in dose dependent suppression of hematopoiesis (reviewed in 1–3). Variables influencing the extent of bone marrow suppression include total dose, dose rate, schedule, shielding, dose uniformity, as well as source-term parameters. Single-dose total body radiation at doses ≥ 1 Gy and dose rates ≥ 1 cGy per minute produce granulocytopenia and thrombocytopenia. Doses > 2 Gy can cause death from infection and bleeding. The 50% lethal dose (LD50) in humans is presumed to be 4–5 Gy based on data in animals. Higher radiation doses carry an increasing risk of death from bone marrow suppression; survival is unlikely after doses > 8–10 Gy. Doses > 15–20 Gy results in death from toxicity to other tissues such as the gastrointestinal tract or central nervous system.
KeywordsToxicity Sarcoma Neutropenia Thrombocytopenia Tempo
Unable to display preview. Download preview PDF.
- 1.UNSCEAR 1982. Ionizing radiation: sources and biologic effects. Report to the General Assembly, Vienna and New York.Google Scholar
- 3.Mettler FA Jr, Moseley RD Jr: Medical Effects of Ionizing Radiation. New York Grune and Stratton. 1985.Google Scholar
- 6.Gale RP. The medical response to radiation and nuclear accidents: Lessons for the future. J Natl Cancer Inst SubmittedGoogle Scholar
- 11.Golde DW, Takaku F (eds). Hematopoietic Stem Cells. New York, Marcel Dekker, Inc. 1985.Google Scholar
- 12.Wright DG, Greenberger JS (eds). Long-Term Bone Marrow Culture. New York, Alan R. Liss, Inc. 1984.Google Scholar
- 13.Metealf D. The molecular biology and functions of the granulocyte-marcophage colony-stimulating factors. Blood 1986; 67: 257–67.Google Scholar
- 18.Donahue RE, Seehra J, Norton C, et al. Hematologic effects of recombinant human interleukin-3 (rhIL-3) and granulocyte/ macrophage colony-stimulating factor (rhGM-CSF) in primates. Proceedings of ASCO, Vol 7, March 1988, p 162.Google Scholar
- 21.Antman K, Griffin J, Elias A, et al. Use of rGM-CSF to ameliorate chemotherapy induced myelosuppression in sarcoma patients. Blood 1987; 70:Suppl 1: 129a.Google Scholar
- 22.Antin JH, Smith BR, Rosenthal DS, et al. Phase I/II study of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in bone marrow failure. Blood 1987; 70:Suppl 1: 129a.Google Scholar
- 24.Butturini AB, De Souza PC, Gale RP, et al. Use of recombinant GM-CSF in the Brazil radiation accident. SubmittedGoogle Scholar